medigraphic.com

2001, Número S1

<< Anterior Siguiente >>

Rev Med Hosp Gen Mex 2001; 64 (S1)


Epidemiología y manejo de los efectos adversos de los antiinflamatorios no esteroides a nivel gastroduodenal

Ramos NF

Idioma: Español
Referencias bibliográficas: 60
Paginas: 20-27
Archivo PDF: 86.91 Kb.


FRAGMENTO

Actualmente los beneficios de los antiinflamatorios no esteroides (AINE) en el manejo de la inflamación están fuera de toda duda.1-4 No obstante, cada día es más evidente que el potencial de este tipo de fármacos para producir efectos colaterales es múltiple, muy importante y muy frecuente;5-12 su mecanismo principal precisamente el mismo por el cual ejercen sus efectos antiinflamatorios y analgésicos benéficos, es decir, la administración de AINE por cualquier vía inhibe de manera generalizada la producción de prostaglandinas, tanto aquellas involucradas en el proceso inflamatorio, como aquellas relacionadas con diversos procesos fisiológicos a nivel gastroduodenal (GD), renal, plaquetario, etc., y de ahí los efectos adversos observados con su empleo a dichos niveles.13-18


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hart FD, Huskisson EC. Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use. Drugs 1984; 27: 232-255.

  2. Brogden RN. Non-steroidal anti-inflammatory analgesics other than salicilates. Drugs 1986; 32: (Suppl 4) 27-45.

  3. Clements PJ, Paulus HE. Nonsteroidal antirheumatic drugs. In: Textbook of Rheumatology. Fifth Edition. Kelly WN, Harris DE, Ruddy S, Sledge CB, Editors. W. B. Saunders Co. Philadelphia 1997: 707-740.

  4. Furst DE, Paulus HE. Aspirin and other nonsteroidal antiinflammatory drugs. In: Arthritis and allied conditions. 12th Edition. McCarty DJ & Koopman WJ. Editors. Lea & Febiger. Philadelphia 1993: 567-602.

  5. Rainsford KD. Mode of action, uses, and side effects of anti-inflammatory drugs. Advances in Anti-Rheumatic Therapy. Rainsford KD, Ed. CRC Press. Boca Raton 1995: 59-95.

  6. Velo GP, Milanino R. Nongastrointestinal adverse reactions to NSAID. J Rheumatol 1990; 17: (Suppl 20) 42-45.

  7. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985; 12: 13-20.

  8. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985; 12: 347-353.

  9. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985; 12: 562-567.

  10. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985; 12: 785-790.

  11. Ramos Niembro F. Antiinflamatorios no esteroideos (Parte I). Del acidoacetilsalicílico (1899) a los inhibidores selectivos de COX-2 (1999). Rev Mex Reumatol 2000: 15: 142- 159. (Parte II) Rev Mex Reumatol 2000; 15: 170-182.

  12. Abramson SB, Weissmann G. The mechanism of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989; 32: 1-9.

  13. Cryer B, Kimmey MB. Gastrointestinal side effects of nonsteroidal antiinflammatory drugs. Am J Med 1998; 105 (1B): 20S-30S.

  14. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rheum 1995; 38: 5-18.

  15. Allison MC, Howatson AG, Torrance CJ et al. Gastrointestinal damage associated with de use of nonsteroidal antiinflammatory drugs. N Eng J Med 1992; 327: 749-754.

  16. Ramos-Niembro F. Gastropatía producida por antiinflamatorios no esteroideos. Una epidemia silenciosa? Rev Universitaria (Mex) (En prensa).

  17. Wolfe M, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Eng J Med 1999; 340: 1888-1899.

  18. Schoen RT, Vender RJ. Mechanism of nonsteroidal antiinflammatory drug-induced gastric damage. Am J Med 1989; 86: 449-458.

  19. Singh G, Ramey DR. NSAID induced gastrointestinal complications: The ARAMIS perspective-1997. J Rheumatol 1998; 25: (Suppl 51) 8-16.

  20. Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Scand J Rheumatol 1996; 25: (Suppl 102) 3-8.

  21. Douthwaite AH, Lintott GAM. Gastroscopic observations of effect of aspirin and certain other substances on stomach. Lancet 1938; ii: 222-225.

  22. Committee on the Safety of Medicines. CSM update: nonsteroidal antiinflammatory drugs and serious gastrointestinal adverse reactions-1. BMJ 1986; 292: 614.

  23. Gibson T. Nonsteroidal anti-inflammatory drugs: another look. Br J Rheumatol 1989; 27: 87-90.

  24. Gabriel SE, Jaakkimainen RL, Bombardier C. The costeffectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993; 36: 447-459.

  25. National Totals for prescriptions of Antiarthritic Drug Therapies in Canada. Montreal: IMS Canada; 1997.

  26. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life treatening complications of peptic ulcerations. Gut 1987; 28: 257-532.

  27. Singh G, Ramey DR, Morfeld D et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch Int Med 1996; 156: 1530-1536.

  28. Avorn JU, Solomon D, Levin R et al. Epidemiologic analysis of prophylactic drug use and NSAID gastropathy. Arthritis Rheum 1996; 39: (Suppl) S185 (Abstract 827).

  29. Tamblyn R, Berkson L, Dauphinee D et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Int Med 1997; 127: 429-438.

  30. Langman MJS, Wainwright P, Lawson DH et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-1078.

  31. Jaszeweski R. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or non steroidal antiinflammatory drugs. J Clin Gastroenterol 1990; 12: 10-13.

  32. Raskin JB. Gastrointestinal effects of nonsteroidal antiinflammatory therapy. Am J Med 1999; 106 (5B):3S-12S.

  33. Labeling revisions for NSAIDs. FDA Drug Bull 1989; 19: 3-4.

  34. Paulus HE. FDA Arthritis Advisory Committee Meeting: Post-marketing surveillance of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1985; 28: 1168-1169.

  35. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105 (1B) 31S-38S.

  36. Rothenberg RJ, Holcomb JP. Guidelines for monitoring NSAIDS. Who listened? J Clin Rheumatol 2000; 5: 258-265.

  37. Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999; 26: (Suppl 56) 18-24.

  38. Agrawal NM, Roth S, Graham DY et al. Comparison of misoprostol and sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Int Med 1991; 115: 195-200.

  39. Ehsanullah RSB, Page MC, Tidesley G et al. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial with ranitidine. BMJ 1988; 297: 1017-1021.

  40. Taha AS, Hudson N, Hawkey CJ et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Eng J Med 1996; 334: 1435-1439.

  41. Walt RP. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Eng J Med 1992: 327: 1575-1580.

  42. Graham DY, White RH, Moreland LW et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Int Med 1993: 119: 257-262.

  43. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal antiinflammatory drugs. A randomized double-blind, placebo controlled trial. Ann Int Med 1995; 123: 241-249.

  44. Simon LS, Hatoum HT, Bittman RM et al. Risk factors for serious non-steroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996: 28: 202-208.

  45. Gabriel SE, Campion ME, O’Fallon M. Patient preferences for nonsteroidal antiinflammatory drug related gastrointestinal complications and their prophylaxis. J Rheumatol 1993; 20: 358-361.

  46. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory. Arthritis Rheum 1998; 41: 16-25.

  47. Yeomans ND, Zsolt T, Juhász L et al. A comparison of omeprazol with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Eng J Med 1998; 338: 719-726.

  48. Hawkey CJ, Karrasch JA, Szczepñski L et al. Omeprazol compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Eng J Med 1998; 338: 727-734.

  49. Fu J, Masferrer J, Seibert K et al. The induction and supression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Clin Invest 1990; 86: 1375-79.

  50. Xie W, Chipman JG, Robertson DL et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci (USA) 1991; 88: 2692-2696.

  51. Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591-1602.

  52. Emery P, Zeidler H, Kvien TK et al. Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999; 354: 2106-2111.

  53. Ehrich EW, Schnitzer T, McIlwain H et al. Effect of specific COX-2 inhibitor in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999; 26: 2438-2447.

  54. Goldstein JL, Silverstein F, Agrawal NM et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1679-1690.

  55. Hawkey C, Laine L, Simon T et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000; 43; 370-377.

  56. Alarcón-Ginori A, Barreda-Abascal R. Celecoxib vs Naproxeno, eficacia y tolerabilidad en osteoartrosis. Estudio multicéntrico comparativo, doble ciego aleatorizado. Rev Mex Reumatol 2000; 15: 95-105.

  57. Singh G, Ramey DR, Triadafilopoulus G. Early experience with selective COX-2 inhibitors: safety profile in over 340,000 patient years of use. Arthritis Rheum 1999; 42: (Suppl) S296.

  58. Silverstein F, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000; 284: 1247-1255.

  59. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng J Med 2000; 343: 1520-1528.

  60. Fries J. NSAID Gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18: 6-10.




2020     |     www.medigraphic.com